Status:
UNKNOWN
Efficacy and Safety of DKB-119 in Patients in Crow's Feet
Lead Sponsor:
Dongkook Pharmaceutical Co., Ltd.
Conditions:
Crow's Feet
Eligibility:
All Genders
19-70 years
Phase:
NA
Brief Summary
To prove the non-inferiority of DKB-119 by evaluating the injecting efficacy and safety DKB-119 and control for patients in crow's feet
Detailed Description
A single center, randomized, subject and evaluator blinded, split-face, pivotal clinical trial
Eligibility Criteria
Inclusion
- Those who are over 19 under 70 ages.
- Those who score 2 or more in the LCL severity evaluation.
- Those who have visually symmetrical crow's feet on both sides.
- Etc.
Exclusion
- Pregnancy and lactating women.
- Etc.
Key Trial Info
Start Date :
November 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06021418
Start Date
November 2 2020
End Date
October 31 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungang-University Hospital
Seoul, South Korea